Addendum

Indacaterol acetate/glycopyrronium bromide/mometasone furoate (asthma) - Addendum to Commission A20-69

Status
Status: Commission completed
Project no.
A20-125
Last updated

Report documents

  1. Addendum

    Indacaterol acetate/glycopyrronium bromide/mometasone furoate (asthma) - Addendum to Commission A20-69

    published on
    Document type
    PDF document, 306 kB, EN, not accessible

Dossier assessment

Indication:

Adults with asthma not adequately controlled with a maintenance combination of a LABA and a high dose of an ICS who experienced one or more asthma exacerbations in the previous year.

Result of dossier assessment:

Added benefit still not proven

Additional information

Federal Joint Committee (G-BA)

2021-02-04: A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A20-125
Commission
Commission awarded on 22.12.2020 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Airways and respiratory system
Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

Connected Projects

  1. Dossier assessment

    Indacaterol acetate/glycopyrronium bromide/mometasone furoate (asthma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-69
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form